Oncotelic Therapeutics Inc. OTLC Archives

WednesdayJan 21, 2026 1:36 pm

QualityStocksNewsBreaks – Oncotelic Therapeutics Inc.’s (OTLC) Deciparticle(TM) Platform Expands Possibilities in Immunology and Oncology

Oncotelic Therapeutics (OTCQB: OTLC) is rapidly emerging in next-generation drug delivery, with a scalable nanotechnology platform that can transform the paradigms of immunology and oncology treatments. “Leveraging Sapu Nano, the company’s clinical-stage nanomedicine, it unveiled new data at the 2025 San Antonio Breast Cancer Symposium (‘SABCS’), highlighting that its Deciparticle(TM) platform can package even the toughest, water-resistant drugs into smaller, uniform nanoparticles that are small enough for effective and safe intravenous use,” reads a recent article. “The platform shows high-level compatibility across different therapeutic categories. All five main macrolide mTOR inhibitors, including temsirolimus, sirolimus, ridaforolimus, Everolimus (Afinitor(R)), and umirolimus, formed stable,…

FridayJan 09, 2026 12:20 pm

QualityStocksNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Advances Nanoparticle Drug Delivery, Prepares First-in-Human Study of IV Everolimus

Oncotelic Therapeutics (OTCQB: OTLC) is positioned at the heart of the evolving landscape of pharmaceutical innovation, applying ultra-small carrier technologies to elevate existing cancer therapies. “The company is pioneering how nanotechnology can enhance bioavailability, precision targeting and therapeutic performance of anticancer compounds,” reads a recent article. “The advantages of nanoparticle delivery in pharma are significant… The contemporary view holds that nanocarrier-enabled formulations may be as transformative for drug delivery as the advent of monoclonal antibodies was for biologics… Into this context, Oncotelic Therapeutics, which in its most recent news has advanced nanoparticle-based delivery strategies through its joint venture entity, involving its…

TuesdayDec 23, 2025 9:45 am

Oncotelic Therapeutics Inc. (OTLC) Unveils Breakthrough Nanomedicine Platform, Expands Everolimus (Afinitor(R)) Pipeline

OTLC’s Deciparticle(TM) platform reliably formulates diverse hydrophobic drugs—including macrolide mTOR inhibitors, peptides, and polyketides—into uniform, IV-ready nanoparticles. Current Preclinical PK data show that Sapu003, the intravenous Deciparticle(TM) formulation of Everolimus (Afinitor(R)), cuts down gastrointestinal drug accumulation by up to 67-fold compared to oral dosing. These advancements highlight a quickly expanding immunology and oncology pipeline built on modular, cGMP-ready nanomedicine engineering. Oncotelic Therapeutics (OTCQB: OTLC) is rapidly emerging as a key player in next-generation drug delivery, with a scalable nanotechnology platform that can transform the paradigms of immunology and oncology treatments. Leveraging Sapu Nano, the company’s clinical-stage nanomedicine, it unveiled new…

WednesdayDec 17, 2025 9:00 am

Oncotelic Therapeutics Inc. (OTLC) Leverages Nanoparticles to Re-Imagine Drug Delivery in Oncology

Research indicates that the advantages of nanoparticle delivery in pharma are significant Oncotelic Therapeutics has advanced nanoparticle-based delivery strategies through its joint venture entity, involving its Deciparticle platform Oncotelic is leveraging the very concepts of nanoparticle-mediated delivery in a real-world clinical context In the evolving landscape of pharmaceutical innovation, nanoparticles are rapidly transforming how we think about drug delivery, and Oncotelic Therapeutics (OTCQB: OTLC) is placing itself at the heart of that transformation by applying ultra-small carrier technologies to elevate existing cancer therapies. The company is pioneering how nanotechnology can enhance bioavailability, precision targeting and therapeutic performance of anticancer compounds.…

MondayDec 15, 2025 11:20 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Collaborates on Peer-Reviewed Biomarker Study in International Journal of Molecular Sciences

Oncotelic Therapeutics (OTCQB: OTLC), in collaboration with the Brush and Key Foundation, announced the publication of a peer-reviewed research article in the International Journal of Molecular Sciences titled “Comparative Tumor Microenvironment Analysis for HCC and PDAC Using KMplotter,” which analyzes the prognostic significance of biomarkers DNMT3A and GMPS across hepatocellular carcinoma and pancreatic ductal adenocarcinoma. Drawing on survival, transcriptomic, and tumor microenvironment data from more than 7,000 patients, the study demonstrates that biomarker relevance is highly context-dependent, shaped by immune composition, metabolic reprogramming, and innate immune signaling pathways, while also highlighting the role of structured mentorship in advancing translational oncology…

MondayDec 15, 2025 9:45 am

Antisense’s Moment: How Rational Design Is Rewriting Drug Development Economics

Industry data shows small molecules achieve 5–10% approval rates over 15–20 years; antisense oligonucleotides (“ASOs”) are shifting the odds through rational design. Six new antisense drugs gained FDA approval in 2023–2024, bringing total approvals above 20; evidence of accelerating regulatory momentum. Oncotelic Therapeutics’ OT-101 (Trabedersen) is the only TGF-β2-specific antisense in Phase 3 trials, targeting pancreatic cancer and other resistant malignancies. The pharmaceutical industry has long faced sobering odds: about 90% of drug candidates fail before reaching market. For small molecules, approval rates hover at very low odds, often requiring up to two decades of development. In oncology, success rates…

ThursdayDec 04, 2025 11:45 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) identifies Biomarker Signature Predicting Sensitivity to IV Sapu003

Oncotelic Therapeutics (OTCQB: OTLC), reports that its 45% owned joint venture, Sapu Nano, has identified a High-RICTOR/Low-RPTOR molecular signature that predicts tumor sensitivity to Sapu003, the company’s intravenous Deciparticle(TM) formulation of everolimus. The biomarker framework, to be presented at the 2025 San Antonio Breast Cancer Symposium, is based on analysis of more than 9,000 tumor samples across 20 cancer types and represents the first prospective selection strategy for IV everolimus. Data show that mTORC2-dominant tumors — including HR+/HER2- breast, lung adenocarcinoma, gastric, renal, ovarian, AML and T-cell malignancies — exhibit heightened mTOR dependency and predicted sensitivity to Sapu003, which overcomes…

TuesdayDec 02, 2025 9:30 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) JV Sapu Nano Presents Data Showing Deciparticle Platform Supports Broad Hydrophobic Drug Formulation

Oncotelic Therapeutics (OTCQB: OTLC) said its 45%-owned joint venture, Sapu Nano, reported new data at the 2025 San Antonio Breast Cancer Symposium showing that its Deciparticle(TM) nanomedicine platform can consistently formulate structurally diverse hydrophobic therapeutics—including macrolide mTOR inhibitors, cyclic and linear peptides, ascomycin macrolactams and polyketides—into sub-20 nm nanoparticles suitable for IV delivery. The Company said the findings confirm Deciparticle as a versatile, cGMP-ready delivery platform backed by ISO-5 manufacturing capabilities that support rapid translation to Phase 1 supply. CEO Dr. Vuong Trieu said the results position Deciparticle as a modular engine for multiple oncology, immunology and peptide drug candidates,…

TuesdayNov 25, 2025 9:00 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Rising Biotech Valuations

Oncotelic Therapeutics (OTCQB: OTLC) announced its inclusion in a BioMedWire editorial highlighting how fair-value adjustments under U.S. GAAP are emerging as key indicators of scientific and commercial progress across the biotech sector. The article spotlights Oncotelic’s upcoming fair-value update on its 45% ownership in JV partner GMP Bio, following an independent assessment showing a significant increase in asset value, reinforcing the company’s position among leaders advancing oncology treatments. To view the full press release, visit https://ibn.fm/BySRI About Oncotelic Therapeutics Inc. Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is…

FridayNov 21, 2025 9:20 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Biotech Valuation Trends

Oncotelic Therapeutics (OTCQB: OTLC) was highlighted in a BioMedWire editorial examining how fair-value remeasurements under GAAP are becoming key indicators of real scientific and commercial progress in late-stage biotech pipelines. The piece notes that Oncotelic is preparing for a significant fair-value remeasurement of its 45% stake in JV entity GMP Bio following a new independent valuation suggesting a potential step-up in asset value, reinforcing the company’s position as it advances its oncology efforts. To view the full press release, visit https://ibn.fm/HKwqM About Oncotelic Therapeutics Inc. Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy…

Site Search

Company Search

Tag: Oncotelic Therapeutics Inc. OTLC